Диссертация (Факторы риска формирования неблагоприятных исходов хронического гепатита С), страница 20
Описание файла
Файл "Диссертация" внутри архива находится в папке "Факторы риска формирования неблагоприятных исходов хронического гепатита С". PDF-файл из архива "Факторы риска формирования неблагоприятных исходов хронического гепатита С", который расположен в категории "". Всё это находится в предмете "медицина" из Аспирантура и докторантура, которые можно найти в файловом архиве МГМУ им. Сеченова. Не смотря на прямую связь этого архива с МГМУ им. Сеченова, его также можно найти и в других разделах. , а ещё этот архив представляет собой кандидатскую диссертацию, поэтому ещё представлен в разделе всех диссертаций на соискание учёной степени кандидата медицинских наук.
Просмотр PDF-файла онлайн
Текст 20 страницы из PDF
– № 2. – P. 463-472.93. Fattovich G., Pantalena M., Zagni I. et al. Effect of hepatitis B and C virus126infections on the natural history of compensated cirrhosis: a cohort study of 297patients // Am. J. Gastroenterol. – 2002. – Vol. 97. – № 11. – P. 2886-2895.94. Fattovich G., Stroffolini T., Zagni I. et al. Hepatocellular carcinoma incirrhosis: incidence and risk factors // Gastroenterology – 2004. – Vol. 127.– № 5.– Suppl 1.
– P. S35-S50.95. Fernández-Rodríguez C., Alonso S., Martinez S. et al. Peginterferon plusribavirin and sustained virological response in HCV-related cirrhosis: outcomesand factors predicting response // Am. J. Gastroenterol. – 2010. – Vol. 105. – №10. – P. 2164-2172.96. Ferri C. Mixed cryoglobulinemia // Orphanet J. Rare Dis. – 2008. – Vol. 3. –№ 25. – P. 1-17.97.
Ferri C., Sebastiani M., Giuggioli D. et al. Mixed cryoglobulinemia:demographic, clinical, and serologic features and survival in 231 patients // Semin.Arthritis Rheum. – 2004. – Vol. 33. – № 6. – P. 355-374.98. Fontana R., Dienstag J., Bonkovsky H. et al. Serum fibrosis markers areassociated with liver disease progression in non-responder patients with chronichepatitis C // Gut – 2010. – Vol. 59. – № 10.
– P. 1401-1409.99. Fontana R., Sanyal A., Ghany M. et al. Factors That Determine theDevelopment and Progression of Gastroesophageal Varices in Patients WithChronic Hepatitis C // Gastroenterology – 2010. – Vol. 138. – № 7. – P. 23212331.100. Freedman N., Everhart J., Lindsay K. et al.
Coffee intake is associated withlower rates of liver disease progression in chronic hepatitis C // Hepatology –2009. – Vol. 50. – № 5. – P. 1360-1369.101. García-Compean D., Jaquez-Quintana J., Maldonado-Garza H. et al.Hepatogenous diabetes. Current views of an ancient problem // Ann.
Hepatol. –2009. – Vol. 8. – № 1. – P. 13-20.102. García-Samaniego J., Rodríguez M., Berenguer J. et al. Hepatocellularcarcinoma in HIV-infected patients with chronic hepatitis C // Am. J.Gastroenterol. – 2001. – Vol. 96. – № 1. – P. 179-183.127103. GBD 2013 Mortality and Causes of Death Collaborators Global, regional, andnational age-sex specific all-cause and cause-specific mortality for 240 causes ofdeath, 1990-2013: a systematic analysis for the Global Burden of Disease Study2013 // Lancet (London, England) – 2015.
– Vol. 385. – № 9963. – P. 117-171.104. Gomez E., Bertot L., Rodriguez Y. et al. The natural history of HCV-relatedcirrhosis and its temporal progression across the different clinical stages // Hepatol.Int. – 2014. – Vol. 8. – № 4. – P. 527-539.105. Gomez E., Rodriguez Y., Bertot L. et al. The natural history of compensatedHCV-related cirrhosis: a prospective long-term study // J. Hepatol. – 2013. – Vol.58. – № 3. – P.
434-444.106. Goossens N., Hoshida Y. Hepatitis C virus-induced hepatocellular carcinoma.// Clin. Mol. Hepatol. – 2015. – Vol. 21. – № 2. – P. 105-114.107. Gower E., Estes C., Blach S. et al. Global epidemiology and genotypedistribution of the hepatitis C virus infection // J. Hepatol. – 2014. – Vol. 61. – №1. – P.
S45-S57.108. Graham C., Baden L., Yu E. et al. Influence of human immunodeficiencyvirus infection on the course of hepatitis C virus infection: a meta-analysis // Clin.Infect. Dis. – 2001. – Vol. 33. – № 4. – P. 562-569.109. Gramenzi A., Andreone P., Fiorino S. et al.
Impact of interferon therapy onthe natural history of hepatitis C virus related cirrhosis // Gut – 2001. – Vol. 48. –№ 6. – P. 843-848.110. Hassan M., Hwang L.-Y., Hatten C. J. et al. Risk factors for hepatocellularcarcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus //Hepatology – 2002. – Vol. 36.
– № 5. – P. 1206-1213.111. Holm L., Carroll L., Cassidy J. et al. The Burden and Determinants of NeckPain in Whiplash-Associated Disorders After Traffic Collisions // J. ManipulativePhysiol. Ther. – 2009. – Vol. 32. – № 2. – P. S61-S69.112. Hope V., Eramova I., Capurro D. et al.
Prevalence and estimation of hepatitisB and C infections in the WHO European Region: a review of data focusing on thecountries outside the European Union and the European Free Trade Association //128Epidemiol. Infect. – 2014. – Vol. 142. – № 2. – P. 270-286.113. Hoshida Y., Villanueva A., Sangiovanni A. et al. Prognostic gene expressionsignatureforpatientswithhepatitisC-relatedearly-stagecirrhosis//Gastroenterology – 2013.
– Vol. 144. – № 5. – P. 1024-1030.114. Hsu C., Huang C., Kao J. et al. Interferon-Based Therapy Decreases Risks ofHepatocellular Carcinoma and Complications of Cirrhosis in Chronic Hepatitis CPatients // PLoS One – 2013. – Vol. 8. – e70458.115.
Hu K., Tong M. The long-term outcomes of patients with compensatedhepatitis C virus-related cirrhosis and history of parenteral exposure in the UnitedStates // Hepatology – 1999. – Vol. 29. – № 4. – P. 1311-1316.116. Huang Y.-W., Yang S.-S., Fu S.-C. et al. Increased risk of cirrhosis and itsdecompensation in chronic hepatitis C patients with new-onset diabetes: anationwide cohort study // Hepatology – 2014. – Vol. 60.
– № 3. – P. 807-814.117. Hung C.-H., Lee C.-M., Lu S.-N. et al. Long-term effect of interferon alpha2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients withhepatitis C virus-related cirrhosis // J. Viral Hepat. – 2006. – Vol. 13. – № 6. – P.409-414.118. Hung C.-H., Lu S.-N., Wang J.-H. et al. Sustained HCV clearance byinterferon-based therapy reduces hepatocellular carcinoma in hepatitis B and Cdually-infected patients // Antivir. Ther. – 2011.
– Vol. 16. – № 7. – P. 959-968.119. Hung C.-H., Wang J.-H., Hu T.-H. et al. Insulin resistance is associated withhepatocellular carcinoma in chronic hepatitis C infection // World J. Gastroenterol.– 2010. – Vol. 16. – № 18. – P. 2265-2271.120. Hutchinson S., Bird S., Goldberg D. Influence of alcohol on the progressionof hepatitis C virus infection: a meta-analysis // Clin. Gastroenterol.
Hepatol. –2005. – Vol. 3. – № 11. – P. 1150-1159.121. Iacobellis A., Perri F., Valvano M. et al. Long-term outcome after antiviraltherapy of patients with hepatitis C virus infection and decompensated cirrhosis //Clin. Gastroenterol. Hepatol. – 2011. – Vol. 9. – № 3. – P. 249-253.122. Ikeda K., Arase Y., Saitoh S.
et al. Prediction model of hepatocarcinogenesis129for patients with hepatitis C virus-related cirrhosis. Validation with internal andexternal cohorts // J. Hepatol. – 2006. – Vol. 44. – № 6. – P. 1089-1097.123. Kanwal F., Hoang T., Kramer J. et al. Increasing prevalence of HCC andcirrhosis in patients with chronic hepatitis C virus infection // Gastroenterology –2011. – Vol. 140. – № 4. – P. 1182-1188.124. Kanwal F., Kramer J., Ilyas J. et al. HCV genotype 3 is associated with anincreased risk of cirrhosis and hepatocellular cancer in a national sample of U.S.Veterans with HCV // Hepatology – 2014.
– Vol. 60. – № 1. – P. 98-105.125. Kim K., Bae S., Lee O. et al. Insulin-like growth factor II induced by hypoxiamay contribute to angiogenesis of human hepatocellular carcinoma // Cancer Res.– 1998. – Vol. 58. – № 2. – P. 348-351.126. King L., Canasto-Chibuque C., Johnson K. et al. A genomic and clinicalprognostic index for hepatitis C-related early-stage cirrhosis that predicts clinicaldeterioration // Gut – 2015. – Vol. 64. – № 8. – P.
1296-1302.127. King L., Johnson K., Zheng H. et al. Host genetics predict clinicaldeterioration in HCV-related cirrhosis // PLoS One – 2014. – Vol. 9. – № 12. –e114747.128. Kobayashi M., Ikeda K., Hosaka T. et al. Natural history of compensatedcirrhosis in the Child-Pugh class A compared between 490 patients with hepatitisC and 167 with B virus infections // J. Med. Virol. – 2006. – Vol.
78. – № 4. – P.459-465.129. Kumar V., Kato N., Urabe Y. et al. Genome-wide association study identifiesa susceptibility locus for HCV-induced hepatocellular carcinoma // Nat. Genet. –2011. – Vol. 43. – № 5. – P. 455-458.130. Lambrecht R., Sterling R., Naishadham D. et al. Iron levels in hepatocytesand portal tract cells predict progression and outcomes of patients with advancedchronic hepatitis C // Gastroenterology – 2011. – Vol. 140. – № 5. – P. 1490-1500.131.
Lee M.-H., Yang H.-I., Lu S.-N. et al. Hepatitis C virus seromarkers andsubsequent risk of hepatocellular carcinoma: long-term predictors from acommunity-based cohort study // J. Clin. Oncol. – 2010. – Vol. 28. – № 30. – P.1304587-4593.132. Li D., Chung R.
Impact of hepatitis C virus eradication on hepatocellularcarcinogenesis // Cancer – 2015. – Vol. 121. – № 17. – P. 2874-2882.133. Lo P., Urabe Y., Kumar V. et al. Identification of a functional variant in theMICA promoter which regulates MICA expression and increases HCV-relatedhepatocellular carcinoma risk // PLoS One – 2013. – Vol. 8.
